The biological nature of sample production means that impurities are likely to be produced alongside the target biopharmaceutical. Regulatory authorities require detailed information on the nature of any such product or process related impurities.
This webinar will consider specific aspects of the primary structure of the protein chain and also look at Post Translational Modifications (PTMs). Process related impurities will then be discussed, with an emphasis on Host Cell Proteins.
Watch this webinar now and join BioPharmaSpec experts, as we share our experiences and expertise of characterizing protein impurities.
